bs-10202R-A594 [Conjugated Primary Antibody]
HPV16 E7 Polyclonal Antibody, ALEXA FLUOR® 594 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: HPV16 E7

Immunogen Range: 11-70/98


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 1489079

Source: KLH conjugated synthetic peptide derived from HPV16 E7 protein

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro.

Conjugation: ALEXA FLUOR® 594

Excitation/ Emission: 590nm/617nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)

Predicted Molecular Weight: 11


Cross Reactive Species: Virus
(HPV16)

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Siyang Zhang. et al. Nocardia rubra cell-wall skeleton influences the development of cervical carcinoma by promoting the antitumor effect of macrophages and dendritic cells. 2022 Jan 07Read more>>
  • Yahang Chen. et al. Human papillomavirus type 16 E7 promotes cell viability and migration in cervical cancer by regulating the miR-23a/HOXC8 axis. J OBSTET GYNAECOL. 2024 Feb 13Read more>>
VALIDATION IMAGES